Status:
COMPLETED
Blood Levels of Tumor Cells in Predicting Response in Patients Receiving First-Line Chemotherapy for Stage IV Breast Cancer
Lead Sponsor:
Institut Curie
Conditions:
Breast Cancer
Eligibility:
All Genders
Brief Summary
RATIONALE: Measuring blood levels of tumor cells in patients with breast cancer may help doctors predict how patients will respond to treatment. PURPOSE: This laboratory study is looking at blood lev...
Detailed Description
OBJECTIVES: Primary * Predict the overall and progression-free survival of patients with stage IV breast cancer by measuring the rate of circulating tumor cells (CTC) before the second course of che...
Eligibility Criteria
Inclusion
- DISEASE CHARACTERISTICS:
- Diagnosis of stage IV breast cancer
- Measurable or evaluable disease
- Scheduled to receive first-line chemotherapy with or without trastuzumab (Herceptin®), depending on HER-2 status
- Histologic block available for confirming pathologic diagnosis and measuring HER-2 status via FISH
- PATIENT CHARACTERISTICS:
- Life expectancy \> 3 months
- No other cancer in the past 5 years except for basal cell skin cancer or epithelial in situ cancer of the cervix
- No geographic, social, or psychiatric reasons that would make treatment impossible
- PRIOR CONCURRENT THERAPY:
- No prior chemotherapy for metastatic disease
Exclusion
Key Trial Info
Start Date :
May 1 2007
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
Estimated Enrollment :
216 Patients enrolled
Trial Details
Trial ID
NCT00898014
Start Date
May 1 2007
Last Update
May 13 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Institut Curie Hopital
Paris, France, 75248